Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Abdominal Radiology
Erschienen in: Abdominal Radiology 11/2020

16.05.2020 | Review

Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings

verfasst von: Mohammed Saleh, Mayur Virarkar, Vlad Bura, Raul Valenzuela, Sanaz Javadi, Janio Szklaruk, Priya Bhosale

Erschienen in: Abdominal Radiology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

To this date, it is a major oncological challenge to optimally diagnose, stage, and manage intrahepatic cholangiocarcinoma (ICC). Imaging can not only diagnose and stage ICC, but it can also guide management. Hence, imaging is indispensable in the management of ICC. In this article, we review the pathology, epidemiology, genetics, clinical presentation, staging, pathology, radiology, and treatment of ICC.
Literatur
1.
Burkhart RA, Pawlik TM. Staging and prognostic models for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729235.PubMedPubMedCentralCrossRef
2.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7–34.
3.
Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, et al. Temporal trends in population‐based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer. 2014;120(19):3058-65.PubMedPubMedCentralCrossRef
4.
Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Annals of surgery. 2008;248(1):84-96.PubMedCrossRef
5.
6.
Nakanuma Y, Tsutsui A, Ren XS, Harada K, Sato Y, Sasaki M. What are the precursor and early lesions of peripheral intrahepatic cholangiocarcinoma? International journal of hepatology. 2014;2014.
7.
London W, McGlynn K. Liver cancer. Cancer epidemiology and prevention. 2006;3:763-86.CrossRef
8.
Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. Journal of gastroenterology and hepatology. 2002;17(10):1049–55.
9.
Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128(3):620-6.PubMedCrossRef
10.
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016;122(9):1349-69.PubMedCrossRef
11.
Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system: World Health Organization; 2010.
12.
Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. Journal of Hepato‐Biliary‐Pancreatic Sciences. 2015;22(2):94-100.PubMedCrossRef
13.
Sasaki A, Aramaki M, Kawano K, Morii Y, Nakashima K, Yoshida T, et al. Intrahepatic peripheral cholangiocarcinoma: mode of spread and choice of surgical treatment. British journal of surgery. 1998;85(9):1206-9.CrossRef
14.
Nakanuma Y, Kakuda Y. Pathologic classification of cholangiocarcinoma: new concepts. Best Practice & Research Clinical Gastroenterology. 2015;29(2):277-93.CrossRef
15.
Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. Journal of Biological Chemistry. 2005;280(25):24053-63.CrossRef
16.
Wink DA, Grisham MB, Mitchell JB, Ford PC. Direct and indirect effects of nitric oxide in chemical reactions relevant to biology. Methods in enzymology. 268: Elsevier; 1996. p. 12–31.
17.
Sirica AE, Lai G-H, Endo K, Zhang Z, Yoon B-I, editors. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Seminars in liver disease; 2002: Copyright© 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New ….
18.
Shaw PH. The role of p53 in cell cycle regulation. Pathology-Research and Practice. 1996;192(7):669-75.CrossRef
19.
Roos E, Soer E, Klompmaker S, Meijer L, Besselink M, Giovannetti E, et al. Crossing borders: a systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. Critical reviews in oncology/hematology. 2019.
20.
Goeppert B, Konermann C, Schmidt CR, Bogatyrova O, Geiselhart L, Ernst C, et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology. 2014;59(2):544-54.PubMedCrossRef
21.
Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PloS one. 2014;9(12):e115383.PubMedPubMedCentralCrossRef
22.
Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nature communications. 2014;5:5696.PubMedCrossRef
23.
Paik KY, Jung JC, Heo JS, Choi SH, Choi DW, Kim YI. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? Journal of gastroenterology and hepatology. 2008;23(5):766-70.PubMedCrossRef
24.
Dhanasekaran R, Hemming AW, Zendejas I, George T, Nelson DR, Soldevila-Pico C, et al. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncology reports. 2013;29(4):1259-67.PubMedPubMedCentralCrossRef
25.
Ariizumi S-i, Yamamoto M. Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis. Surgery today. 2015;45(6):682–7.
26.
Shin SK, Choi DJ, Kim JH, Kim YS, Kwon OS. Characteristics of contrast-enhanced ultrasound in distinguishing small (≤ 3 cm) hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Medicine. 2018;97(41).
27.
DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Annals of surgery. 2007;245(5):755.PubMedPubMedCentralCrossRef
28.
NICHOLS JC, GORES GJ, LARUSSO NF, WIESNER RH, NAGORNEY DM, RITTS JR RE, editors. Diagnostic role of serum CA 19–9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clinic Proceedings; 1993: Elsevier.
29.
Chen C-Y, Shiesh S-C, Tsao H-C, Lin X-Z. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis. Hepato-gastroenterology. 2002;49(45):616-20.PubMed
30.
Vauthey J-N, Lauwers GY, Esnaola NF, Do K-A, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. Journal of clinical oncology. 2002;20(6):1527-36.PubMedCrossRef
31.
Jonas S, Thelen A, Benckert C, Biskup W, Neumann U, Rudolph B, et al. Extended liver resection for intrahepatic cholangiocarcinoma: a comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification. Annals of surgery. 2009;249(2):303-9.PubMedCrossRef
32.
Nathan H, Aloia TA, Vauthey J-N, Abdalla EK, Zhu AX, Schulick RD, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Annals of surgical oncology. 2009;16(1):14-22.PubMedCrossRef
33.
Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC‐IHCC‐2009 study group. Cancer. 2011;117(10):2170–7.
34.
De Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. Journal of Clinical Oncology. 2011;29(23):3140-5.PubMedCrossRef
35.
Igami T, Ebata T, Yokoyama Y, Sugawara G, Takahashi Y, Nagino M. Staging of peripheral-type intrahepatic cholangiocarcinoma: appraisal of the new TNM classification and its modifications. World journal of surgery. 2011;35(11):2501.PubMedCrossRef
36.
Doussot A, Gonen M, Wiggers JK, Groot-Koerkamp B, DeMatteo RP, Fuks D, et al. Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models. Journal of the American College of Surgeons. 2016;223(3):493–505. e2.
37.
Hwang S, Lee Y-J, Song G-W, Park K-M, Kim K-H, Ahn C-S, et al. Prognostic impact of tumor growth type on 7th AJCC staging system for intrahepatic cholangiocarcinoma: a single-center experience of 659 cases. Journal of Gastrointestinal Surgery. 2015;19(7):1291-304.PubMedCrossRef
38.
Spolverato G, Bagante F, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. Journal of surgical oncology. 2017;115(6):696-703.PubMedCrossRef
39.
Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8 th edition updates. Chinese clinical oncology. 2018;7(5).
40.
Nathan H, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Current opinion in gastroenterology. 2010;26(3):269-73.PubMedCrossRef
41.
Bloom CM, Langer B, Wilson SR. Role of US in the detection, characterization, and staging of cholangiocarcinoma. Radiographics. 1999;19(5):1199-218.PubMedCrossRef
42.
Wibulpolprasert B, Dhiensiri T. Peripheral cholangiocarcinoma: sonographic evaluation. Journal of clinical ultrasound. 1992;20(5):303-14.PubMedCrossRef
43.
Soyer P, Bluemke DA, Reichle R, Calhoun PS, Bliss DF, Scherrer A, et al. Imaging of intrahepatic cholangiocarcinoma: 1. Peripheral cholangiocarcinoma. AJR American journal of roentgenology. 1995;165(6):1427–31.
44.
Li C, Wang W, Ding H, Huang B, Cao J, Mao F, et al. Value of contrast‐enhanced sonography in the diagnosis of peripheral intrahepatic cholangiocarcinoma. Journal of Clinical Ultrasound. 2011;39(8):447-53.PubMedCrossRef
45.
Li R, Zhang X, Ma K-S, Li X-W, Xia F, Zhong H, et al. Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis. Abdominal imaging. 2013;38(1):112-9.PubMedCrossRef
46.
Chen T, Chang X, Lv K, Wang Y, Fu X, Tan L, et al. contrast-enhanced Ultrasound features of intrahepatic cholangiocarcinoma: A new perspective. Scientific Reports. 2019;9(1):1-8.CrossRef
47.
Kong W-T, Wang W-P, Zhang W-W, Qiu Y-D, Ding H, Huang B-J. Contribution of Contrast–Enhanced Sonography in the Detection of Intrahepatic Cholangiocarcinoma. Journal of Ultrasound in Medicine. 2014;33(2):215-20.PubMedCrossRef
48.
Xu H, Chen L, Liu L, Zhang Y, Guo L, Liu C. Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. The British journal of radiology. 2012;85(1016):1029-37.PubMedPubMedCentralCrossRef
49.
Chen L-D, Xu H-X, Xie X-Y, Xie X-H, Xu Z-F, Liu G-J, et al. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. European radiology. 2010;20(3):743-53.PubMedCrossRef
50.
Seitz K, Strobel D, Bernatik T, Blank W, Friedrich-Rust M, von Herbay A, et al. Contrast-Enhanced Ultrasound (CEUS) for the Characterization of Focal Liver Lesions–Prospective Comparison in Clinical Practice: CEUS vs. CT (DEGUM Multicenter Trial) Parts of this Manuscript were presented at the Ultrasound Dreiländertreffen 2008, Davos. Ultraschall in der Medizin-European Journal of Ultrasound. 2009;30(04):383–9.
51.
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver–update 2012. Ultraschall in der Medizin-European Journal of Ultrasound. 2013;34(01):11-29.
52.
Vilana R, Forner A, Bianchi L, García‐Criado Á, Rimola J, Rodríguez de Lope C, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast‐enhanced ultrasound. Hepatology. 2010;51(6):2020–9.
53.
Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. Journal of hepatology. 2006;45(1):43-50.PubMedCrossRef
54.
Tsunematsu S, Chuma M, Kamiyama T, Miyamoto N, Yabusaki S, Hatanaka K, et al. Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. Abdominal imaging. 2015;40(6):1492-9.PubMedCrossRef
55.
Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? The oncologist. 2006;11(8):913-22.PubMedCrossRef
56.
Ueda K, Terada T, Nakanuma Y, Matsui O. Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a morphometric study. Human pathology. 1992;23(6):619-26.PubMedCrossRef
57.
Kim Y-Y, Kim M-J, Kim EH, Roh YH, An C. Hepatocellular carcinoma versus other hepatic malignancy in cirrhosis: performance of LI-RADS version 2018. Radiology. 2019;291(1):72-80.PubMedCrossRef
58.
Choi SH, Lee SS, Kim SY, Park SH, Park SH, Kim KM, et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid–enhanced mr imaging and dynamic CT. Radiology. 2017;282(3):771-81.PubMedCrossRef
59.
Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. Journal of computer assisted tomography. 1999;23(5):670-7.PubMedCrossRef
60.
61.
Ariizumi SI, Kotera Y, Takahashi Y, Katagiri S, Chen IP, Ota T, et al. Mass‐forming intrahepatic cholangiocarcinoma with marked enhancement on arterial‐phase computed tomography reflects favorable surgical outcomes. Journal of surgical oncology. 2011;104(2):130-9.PubMedCrossRef
62.
Fujita N, Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y, et al. Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT-Correlation with clinicopathological findings. European radiology. 2017;27(2):498-506.PubMedCrossRef
63.
Okami J, Dono K, Sakon M, Tsujie M, Hayashi N, Fujiwara Y, et al. Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe. Journal of gastrointestinal surgery. 2003;7(7):850-6.PubMedCrossRef
64.
Yamamoto Y, Türkoğlu MA, Aramaki T, Sugiura T, Okamura Y, Ito T, et al. Vascularity of intrahepatic cholangiocarcinoma on computed tomography is predictive of lymph node metastasis. Annals of surgical oncology. 2016;23(4):485-93.PubMedCrossRef
65.
Baheti AD, Tirumani SH, Shinagare AB, Rosenthal MH, Hornick JL, Ramaiya NH, et al. Correlation of CT patterns of primary intrahepatic cholangiocarcinoma at the time of presentation with the metastatic spread and clinical outcomes: retrospective study of 92 patients. Abdominal imaging. 2014;39(6):1193-201.PubMedCrossRef
66.
Seo N, Kim DY, Choi J-Y. Cross-sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis. American Journal of Roentgenology. 2017;209(2):W64-W75.PubMedCrossRef
67.
Min JH, Kim YK, Choi S-Y, Kang TW, Lee SJ, Kim JM, et al. Intrahepatic Mass-forming Cholangiocarcinoma: Arterial Enhancement Patterns at MRI and Prognosis. Radiology. 2019;290(3):691-9.PubMedCrossRef
68.
You M-W, Yun S. Differentiating between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced MRI features: a systematic review and meta-analysis. Clinical radiology. 2019;74(5):406. e9-. e18.
69.
ennedige TP, Hallinan JT, Leung FP, Teo LL, Iyer S, Wang G, et al. Comparison of magnetic resonance elastography and diffusion-weighted imaging for differentiating benign and malignant liver lesions. European radiology. 2016;26(2):398-406.PubMedCrossRef
70.
Fábrega-Foster K, Ghasabeh MA, Pawlik TM, Kamel IR. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary surgery and nutrition. 2017;6(2):67.PubMedPubMedCentralCrossRef
71.
Lewis S, Besa C, Wagner M, Jhaveri K, Kihira S, Zhu H, et al. Prediction of the histopathologic findings of intrahepatic cholangiocarcinoma: qualitative and quantitative assessment of diffusion-weighted imaging. European radiology. 2018;28(5):2047-57.PubMedCrossRef
72.
Cui X-Y, Chen H-W, Cai S, Bao J, Tang Q-F, Wu L-Y, et al. Diffusion-weighted MR imaging for detection of extrahepatic cholangiocarcinoma. European journal of radiology. 2012;81(11):2961-5.PubMedCrossRef
73.
ee J, Kim SH, Kang TW, Song KD, Choi D, Jang KT. Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging as a preoperative prognostic marker. Radiology. 2016;281(1):119-28.PubMedCrossRef
74.
Choi SH, Lee SS, Kim SY, Park SH, Park SH, Kim KM, et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid–enhanced mr imaging and dynamic CT. Radiology. 2016;282(3):771-81.PubMedCrossRef
75.
Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816-30.PubMedPubMedCentralCrossRef
76.
Park HS, Lee JM, Choi J-Y, Lee MW, Kim HJ, Han JK, et al. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. American Journal of Roentgenology. 2008;190(2):396-405.PubMedCrossRef
77.
Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta oncologica. 2009;48(7):1034-43.PubMedCrossRef
78.
Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, et al. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology. 2012;264(1):285-94.PubMedCrossRef
79.
Pandey A, Pandey P, Aliyari Ghasabeh M, Najmi Varzaneh F, Shao N, Khoshpouri P, et al. Unresectable intrahepatic cholangiocarcinoma: multiparametric MR imaging to predict patient survival. Radiology. 2018;288(1):109-17.PubMedCrossRef
80.
Annunziata S, Caldarella C, Pizzuto DA, Galiandro F, Sadeghi R, Giovanella L, et al. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis. BioMed research international. 2014;2014.
81.
Hu J-H, Tang J-h, Lin C-H, Chu Y-Y, Liu N-J. Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis. Journal of Investigative Medicine. 2018;66(1):52–61.
82.
Park TG, Yu Y-D, Park BJ, Cheon GJ, Oh SY, Kim D-S, et al. Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma. Clinical nuclear medicine. 2014;39(1):1-7.PubMedCrossRef
83.
Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. Journal of the American College of Surgeons. 2008;206(1):57-65.PubMedCrossRef
84.
Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, et al. Usefulness of 18F‐fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. Journal of gastroenterology and hepatology. 2008;23(5):759-65.PubMedCrossRef
85.
Nguyen KT, Steel J, Vanounou T, Tsung A, Marsh JW, Geller DA, et al. Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin-positive result a contraindication to resection? Annals of surgical oncology. 2009;16(12):3308-15.PubMedPubMedCentralCrossRef
86.
Ma KW, Cheung TT, She WH, Chok KSH, Chan ACY, Dai WC, et al. Diagnostic and prognostic role of 18-FDG PET/CT in the management of resectable biliary tract cancer. World journal of surgery. 2018;42(3):823-34.PubMedCrossRef
87.
Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. International Journal of Radiation Oncology Biology Physics. 2009;73(1):148-53.CrossRef
88.
Ikeno Y, Seo S, Iwaisako K, Yoh T, Nakamoto Y, Fuji H, et al. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18 F-FDG-PET is associated with the KRAS mutation status and prognosis. Journal of translational medicine. 2018;16(1):95.PubMedPubMedCentralCrossRef
89.
Kirchner J, Sawicki LM, Deuschl C, Grüneisen J, Beiderwellen K, Lauenstein TC, et al. 18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine. PloS one. 2017;12(7):e0180349.PubMedPubMedCentralCrossRef
90.
Van der Gaag N, Kloek J, de Castro S, Busch O, Van Gulik T, Gouma D. Preoperative biliary drainage in patients with obstructive jaundice: history and current status. Journal of Gastrointestinal Surgery. 2009;13(4):814-20.PubMedCrossRef
91.
Spolverato G, Vitale A, Cucchetti A, Popescu I, Marques HP, Aldrighetti L, et al. Can hepatic resection provide a long‐term cure for patients with intrahepatic cholangiocarcinoma? Cancer. 2015;121(22):3998-4006.PubMedCrossRef
92.
Edge SB. AJCC cancer staging manual. Springer. 2010;7:97-100.
93.
Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013;153(6):811-8.PubMedPubMedCentralCrossRef
94.
Buettner S, van Vugt JL, IJzermans JN, Koerkamp BG. Intrahepatic cholangiocarcinoma: current perspectives. OncoTargets and therapy. 2017;10:1131.
95.
Giuliante F, Gauzolino R, Vellone M, Ardito F, Murazio M, Nuzzo G. Liver resection for intrahepatic cholangiocarcinoma. Tumori. 2005;91(6):487.PubMedCrossRef
96.
Pulitano C, Crawford M, Joseph D, Aldrighetti L, Sandroussi C. Preoperative assessment of postoperative liver function: the importance of residual liver volume. Journal of surgical oncology. 2014;110(4):445-50.PubMedCrossRef
97.
Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Annals of surgery. 2009;250(4):540-8.PubMedCrossRef
98.
Kim HJ, Kim CY, Park EK, Hur YH, Koh YS, Kim HJ, et al. Volumetric analysis and indocyanine green retention rate at 15 min as predictors of post‐hepatectomy liver failure. HPB. 2015;17(2):159-67.PubMedCrossRef
99.
Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma-a population-based study. Annals of surgical oncology. 2008;15(2):600-8.PubMedCrossRef
100.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine. 2010;362(14):1273-81.CrossRef
101.
Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Annals of oncology. 2013;25(2):391-8.PubMedCrossRef
102.
Smith GW, Bukowski R, Hewlett JS, Groppe CW. Hepatic artery infusion of 5‐fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer. 1984;54(8):1513-6.PubMedCrossRef
103.
Kemeny NE, Schwartz L, Gönen M, Yopp A, Gultekin D, D’Angelica MI, et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results. Oncology. 2011;80(3-4):153-9.PubMedPubMedCentralCrossRef
104.
Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. Journal of hepatology. 2015;62(5):1187-95.PubMedCrossRef
105.
Mouli S, Memon K, Baker T, Benson III AB, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. Journal of Vascular and Interventional Radiology. 2013;24(8):1227-34.PubMedPubMedCentralCrossRef
106.
Al-Adra D, Gill R, Axford S, Shi X, Kneteman N, Liau S-S. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. European Journal of Surgical Oncology (EJSO). 2015;41(1):120-7.PubMedCrossRef
107.
Kim JH, Won HJ, Shin YM, Kim PN, Lee S-G, Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. European journal of radiology. 2011;80(3):e221-e5.PubMedCrossRef
108.
Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. Journal of Vascular and Interventional Radiology. 2015;26(7):943-8.PubMedCrossRef
109.
Koay EJ, Odisio BC, Javle M, Vauthey J-N, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary surgery and nutrition. 2017;6(2):105.PubMedPubMedCentralCrossRef
110.
Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. Journal of Clinical Oncology. 2016;34(3):219.PubMedCrossRef
111.
Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. Journal of Hepato‐Biliary‐Pancreatic Surgery. 2001;8(2):154-7.PubMedCrossRef
112.
Oliveira IS, Kilcoyne A, Everett JM, Mino-Kenudson M, Harisinghani MG, Ganesan K. Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management. Abdominal radiology. 2017;42(6):1637-49.PubMedCrossRef
113.
Ringe KI, Wacker F. Radiological diagnosis in cholangiocarcinoma: application of computed tomography, magnetic resonance imaging, and positron emission tomography. Best Practice & Research Clinical Gastroenterology. 2015;29(2):253-65.CrossRef
114.
Mar WA, Shon AM, Lu Y, Jonathan HY, Berggruen SM, Guzman G, et al. Imaging spectrum of cholangiocarcinoma: role in diagnosis, staging, and posttreatment evaluation. Abdominal Radiology. 2016;41(3):553-67.PubMedCrossRef
115.
116.
Jadvar H, Henderson RW, Conti PS. [F-18] fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. Journal of computer assisted tomography. 2007;31(2):223-8.PubMedCrossRef
117.
Cameron K, Golan S, Simpson W, Peti S, Roayaie S, Labow D, et al. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdominal imaging. 2011;36(4):463-71.PubMedCrossRef
118.
Ribero D, Chun YS, Vauthey J-N, editors. Standardized liver volumetry for portal vein embolization. Seminars in interventional radiology; 2008: © Thieme Medical Publishers.
Metadaten
Titel
Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings
verfasst von
Mohammed Saleh
Mayur Virarkar
Vlad Bura
Raul Valenzuela
Sanaz Javadi
Janio Szklaruk
Priya Bhosale
Publikationsdatum
16.05.2020
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 11/2020
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-020-02559-7

Weitere Artikel der Ausgabe 11/2020

Abdominal Radiology 11/2020 Zur Ausgabe

Review

Tumors presenting in both pediatric and adult patients: a case-based review of pathology and imaging features for the radiologist

Review

Imaging features, complications and differential diagnoses of abdominal cystic lymphangiomas

Special Section: Chronic liver disease

Natural history of hepatocellular carcinoma after stereotactic body radiation therapy

Hollow Organ GI

Multiple metabolic parameters and visual assessment of 18F-FDG uptake heterogeneity of PET/CT in advanced gastric cancer and primary gastric lymphoma

Kidneys, Ureters, Bladder, Retroperitoneum

Differential diagnosis of hypervascular ultra-small renal cell carcinoma and renal angiomyolipoma with minimal fat in early stage by using thin-section multidetector computed tomography

Interventional Radiology

Transjugular intrahepatic portosystemic shunt placement: portal vein puncture guided by 3D/2D image registration of contrast-enhanced multi-detector computed tomography and fluoroscopy

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet

29.03.2024 | Diagnostische Radiologie | Nachrichten

Studie bestätigt Potenzial von KI in der Radiologie

26.03.2024 | Koronare Herzerkrankung | Nachrichten

Quantitative Angiografie könnte IVUS-Alternative darstellen
weitere anzeigen

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen